Clinical trial NCT04796038: Rise Semi Compliant Balloon Study in Patient With CAD
Official title: Evaluation of the Acute Safety and Device Success of the RISE SC Coronary Balloon Dilatation Catheter When Used as a Dilatation Device in the Stenotic Portion of a Coronary Artery or Bypass Graft in Patients With Coronary Artery Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Coronary Artery Disease
Lead sponsor: Biosensors Europe SA
Sponsor class: INDUSTRY
First posted: 2021-03-12
Enrollment: 67
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Single arm, prospective, multi-center, trial designed to enrol approximately 66 patients. All patients will undergo PCI using at least one RISE SC balloon as per routine clinical practice and will be followed until discharge for data collection. Patients will be enrolled in up to 5 investigational sites in Switzerland.

The patients will be followed up until discharge or until 7 days, whichever comes first.


Eligibility criteria: Inclusion Criteria:

* General Inclusion Criteria

  1. Subject must be at least 18 years of age.
  2. Subject or a legally authorised representative must provide written informed consent prior to any study related procedure.
  3. Subject must have stenotic lesion(s) in native coronary arteries or bypass grafts that are suitable for percutaneous coronary intervention.
  4. Subject must agree to undergo all protocol-required follow-up procedures.
  5. Subject must agree not to participate in any other clinical study during hospitalisation for the index procedure.
* Angiographic Inclusion Criteria All angiographic inclusion criteria are based on visual estimation.

  1. De novo or restenotic lesions in native coronary arteries or bypass grafts.
  2. A maximum of two lesions, with either both in one vessel or one lesion in each of two vessels.
  3. The target lesion(s) must have a diameter stenosis of ≥ 50% by visual estimation or online quantitative coronary angiography (QCA) and may include chronic total occlusions (CTO).

Exclusion Criteria:

* General Exclusion Criteria

  1. Planned use of a non-study angioplasty balloon during the procedure for pre-dilatation or dilatation of the lesion.
  2. Subject has a known hypersensitivity or contraindication to aspirin, heparin/bivalirudin, other anti-platelet medications, or sensitivity to contrast media, which cannot be adequately pre-treated.
  3. Subject has a platelet count \< 100,000 cells/mm3 or \> 700,000 cells/mm3.
  4. Subject is currently participating in an investigational study that may confound the treatment or outcomes of this study.
  5. Subject is pregnant or nursing. Female subjects of child-bearing potential must have a negative pregnancy test done within 7 days prior to the index procedure per site standard test.
* Angiographic Exclusion Criteria All angiographic exclusion criteria are based on visual estimation.

  1. Unprotected left main coronary artery disease
  2. More than two lesions requiring treatment. Tandem lesions, defined as multiple, focal lesions that can be covered by one balloon, will be considered as a single lesion.
  3. Coronary artery spasm in the absence of significant stenosis.
  4. Anticipated need for plaque modification using rotational/orbital atherectomy or intravascular lithotripsy. Note: The use of scoring or cutting balloons after (pre)-dilatation with the study device is allowed.
  5. Additional clinically significant lesion(s) in any coronary arteries or bypass grafts for which PCI may be required during hospitalization for the index procedure (in-hospital staged PCI).

Primary outcomes:
measure: Percentage of treated lesions with device success defined as:
timeFrame: During the interventional procedure
Secondary outcomes:
measure: Percentage of patients with Individual components of device success defined as:
timeFrame: During the interventional procedure
measure: Percentage of patients with Procedural success defined as:
timeFrame: 1 - 7 Days
measure: Percentage of patients with Target Lesion Failure (TLF)
timeFrame: 1 - 7 Days
Other outcomes:
Locations:
city: Sion
country: Switzerland
facility: HVS
state: Valis
city: Lausanne
country: Switzerland
facility: CHUV
state: Vaud
city: Geneva
country: Switzerland
facility: HUG
Study officials:
affiliation: Hôpitaux universitaires de Genève (HUG)
name: Marco Roffi, Dr.
role: PRINCIPAL_INVESTIGATOR
References: